



February 11, 2025

The General Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001

COMPANY CODE : **BAYERCROP**
SCRIP CODE : **506285**

Dear Sir / Madam,

Sub.: Outcome of Board Meeting – February 11, 2025.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at their meeting held today i.e., February 11, 2025, has inter alia,

1. Noted the letter of Resignation of Mr. Simon Johannes Britsch (DIN: 09194547) as the Whole-Time Director (Executive) and Chief Financial Officer (CFO) of the Company with effect from February 28, 2025, due to his planned repatriation to Bayer AG. Consequently, he shall also cease to be a member of Stakeholders' Relationship Committee, Corporate Social Responsibility & Environmental, Social and Governance Committee and Risk Management Committee as on that date.
2. Noted the letter of Resignation of Dr. Miriam Holstein (DIN: 10458293) as the Non-Executive Non-Independent Director of the Company with effect from February 28, 2025, due to cessation of her active employment with Bayer AG.
3. Approved appointment of Mr. Vinit Rajesh Jindal (Mr. Vinit Jindal) (DIN: 10849465) as an Additional Director and Whole-Time Director designated as Executive Director and Chief Financial Officer (CFO) of the Company with effect from March 01, 2025, based on the recommendations of Nomination and Remuneration Committee, subject to the approval of Shareholders and Central Government, if required.
4. Approved appointment of Ms. Jana Marlen Ackermann (DIN: 10849470) as an Additional Director (Non- Executive Non-Independent) of the Company with effect from March 01, 2025, based on the recommendations of Nomination and Remuneration Committee, subject to the approval of Shareholders.

Bayer CropScience Ltd.
CIN: L24210MH1958PLC011173

Registered and Corporate Office:
Bayer House
Central Avenue
Hiranandani Estate
Thane (West) – 400 607
Maharashtra, India

Tel : +91 22 2531 1234
Fax : +91 22 2545 5063
www.bayer.in
www.cropscience.bayer.com

RESTRICTED



5. Approved to designate Ms. Priya D'Cruz, Cluster HR Lead South Asia, as the Senior Management Personnel (SMP) of the Company with effect from February 12, 2025, based on the recommendations of Nomination and Remuneration Committee.

Disclosure under Regulation 30 read with Part A of Schedule III of Listing Regulations read along with SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023, is enclosed as Annexure 1, Annexure 2, Annexure 3, Annexure 4, Annexure 5.

Further, please take a note that the Board Meeting commenced at 5:00 p.m. (IST) and concluded at 6:00 p.m. (IST).

We request you to take the same on record.

Thanking You.

Yours faithfully,

for **Bayer CropScience Limited**

Bharati Shetty

Company Secretary and Compliance Officer
(Membership No.: ACS 24199)

Encl.: As above

RESTRICTED



Annexure 1

Name	Mr. Simon Johannes Britsch
Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Resignation due to his planned repatriation to Bayer AG.
Date of appointment/ reappointment/ cessation (as applicable) & term of appointment/ re-appointment	February 28, 2025
Brief profile (in case of appointment)	NA
Disclosure of relationship between Directors (in case of appointment of a director)	NA

January 31, 2025

To,
The Board of Directors
Bayer CropScience Limited
Bayer House, Central Avenue,
Hiranandani Estate,
Thane (West) – 400 607.

Dear Board Members,


Subject: Resignation as the Whole-time Director (Executive) and Chief Financial Officer of the Company

This is to inform the Board that I hereby tender my resignation as the Whole-time Director (Executive) and Chief Financial Officer of the Company with effect from close of business hours on February 28, 2025 due to my planned repatriation to Bayer AG. Consequently, I will also be stepping down as the Member of Corporate Social Responsibility Committee, Stakeholders Relationship Committee and Risk Management Committee of the Company as on that date.

I take this opportunity to thank the Board and other Committee members for the support extended to me during my tenure.

Thanking you,

Yours faithfully,



Simon Johannes Britsch

Whole-time Director (Executive) and
Chief Financial Officer
DIN: 09194547

RESTRICTED



Annexure 2

Name	Dr. Miriam Holstein
Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Resignation due to cessation of her active employment with Bayer AG.
Date of appointment/ reappointment/ cessation (as applicable) & term of appointment/re-appointment	February 28, 2025
Brief profile (in case of appointment)	NA
Disclosure of relationship between Directors (in case of appointment of a director)	NA

January 31, 2025

To
The Board of Directors
Bayer CropScience Limited
Bayer House, Central Avenue
Hiranandani Estate,
Thane (West) – 400 607

Subject: Resignation as a Non-Executive Non- Independent Director of the Company


Dear Board of Directors,

This is to inform the Board that I hereby tender my resignation as Non-Executive Non - Independent Director of the Company with effect from close of business hours on February 28, 2025 due to cessation of my active employment with Bayer AG.

I take this opportunity to thank the Board members for the support extended to me during my tenure.

Thanking you.

Yours faithfully,

Signature:  _____

Name: Dr. Miriam Holstein

DIN: 10458293

Place: Leverkusen, Germany

RESTRICTED



Annexure 3

Name	Mr. Vinit Rajesh Jindal (Mr. Vinit Jindal)
Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of Mr. Vinit Jindal as an Additional Director and Whole-Time Director (Executive) and Chief Financial Officer (CFO) of the Company.
Date of appointment/ re-appointment/cessation (as applicable) & term of appointment/re-appointment	March 01, 2025
Brief profile (in case of appointment)	<p>Mr. Vinit Jindal began his career at Bayer in Germany as an International Controlling Trainee in 2001, later becoming Head of Accounting for Bayer CropScience Ltd India in 2005. His diverse experience spans roles in Bayer HealthCare Germany's global finance team from 2003 to 2005 and leading the India Strategy function from 2008 to 2010, where he successfully managed key divestments, acquisitions, and other transformation initiatives. From 2011 to 2014, he was a member of the CropScience Leadership Team as Head of Product Supply, overseeing Supply Chain Management, Site Logistics, Cost Management, and relationships with third-party manufacturers. Mr. Jindal has held several leadership positions, including Group CFO for Bayer Southern Africa and Managing Director and CFO for Bayer in the Philippines, before assuming his current role as Group CFO for the UK & Ireland cluster in 2021.</p> <p>A Chartered Accountant and Cost Accountant, Vinit is an alumnus of the Indian Institute of Management, Calcutta and holds a Bachelor's degree in Commerce from Mumbai University. His early career included roles at Siemens in India, where he not only focused on accounting but also served as an in-house SAP consultant.</p>
Disclosure of relationship between Directors (in case of appointment of a director)	Mr. Vinit Jindal is not related to any Director(s) of the Company as defined under the provisions of Section 2(77) of the Companies Act, 2013.



Annexure 4

Name	Ms. Jana Marlen Ackermann
Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Appointment of Ms. Jana Marlen Ackermann as an Additional Director (Non-Executive & Non-Independent) of the Company.
Date of appointment/ reappointment/cessation (as applicable) & term of appointment/ re-appointment	March 01, 2025
Brief profile (in case of appointment)	Ms. Jana Marlen Ackermann has been with Bayer since 2004 in various roles with increasing responsibilities. She started her career at the company's headquarters in Germany as an Internal Auditor and held positions in Strategy, Procurement and Finance and Business Development in the years thereafter. From 2020 to 2022 Ms. Ackermann headed the Investor Relations Corporate and Consumer Health Team. In 2022, she moved to Brazil assuming the role of CFO for the Bayer group with Brazil being the 2nd largest country for the Bayer group worldwide. Since September 2024, she has been taking over as the CropScience Finance Head for Asia. She has studied Business Administration in Germany and Spain as well as Political Science and holds an MBA and a Bachelor of Arts in Political Science.
Disclosure of relationship between Directors (in case of appointment of a director)	Ms. Jana Marlen Ackermann is not related to any Director(s) of the Company as defined under the provisions of Section 2(77) of the Companies Act, 2013.



Annexure 5

Name	Ms. Priya D’Cruz
Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise	Designation of Ms. Priya D’Cruz, Cluster HR Lead South Asia, as the Senior Management Personnel of the Company.
Date of appointment/ re-appointment/cessation (as applicable) & term of appointment/re-appointment	February 12, 2025
Brief profile (in case of appointment)	<p>Ms. Priya D’Cruz joined Bayer in 1995 and has held roles of increasing responsibility across the different verticals of HR and varied industries like Pharmaceuticals, Chemicals and Technology. She has strengths in organizational development and transformation, partnering with leadership teams to drive the talent agenda, engagement and performance in environments experiencing significant external and internal organizational change.</p> <p>Prior to her appointment to this role, she led the HR Partnering team for CropScience and was Head DE&I for South Asia since 2019. She steered the DEI agenda shaping inclusive people policies and tailored talent attraction programs to significantly improve the companies gender representation resulting in Bayer being featured among the Best Companies for Women over 5 consecutive years. She has diverse partnering experience working in roles such as the Regional HR Head of CropScience for APAC2, HR Partner for the Material Science business, the India Delivery Centre (Bayer’s offshore IT Capability Centre) and Enabling Functions. She has held expert roles as Centre of Expertise for Compensation & Benefits, South Asia and general management roles leading the HR Services organization & digitally transforming the HR service delivery model.</p> <p>Ms. Priya D’Cruz has completed her Master’s in Business Administration from the Indo German Training Centre and holds a BA Economics from Mumbai University. She is a certified change practitioner from Ashridge University & coach from the Neuro Leadership Institute.</p>
Disclosure of relationship between Directors (in case of appointment of a director)	NA



February 11, 2025

The General Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400 001

COMPANY CODE : **BAYERCROP**
SCRIP CODE : **506285**

Dear Sir / Madam,

Sub.: Unaudited Financial Results along with Limited Review Report of the Company for the quarter ended December 31, 2024

Pursuant to 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Board of Directors at their meeting held today i.e., February 11, 2025, has inter alia approved the Unaudited Financial Results of the Company for the quarter ended on December 31, 2024. We attach a copy of the same along with the Limited Review Report thereon from the Statutory Auditors, Deloitte Haskins & Sells LLP (ICAI Firm Registration No. 117366W/W-100018).

Further, please take a note that the Board Meeting commenced at 5:00 p.m. (IST) and concluded at 6:00 p.m. (IST).

We request you to take the same on record.

Thanking You.

Yours faithfully,

for **Bayer CropScience Limited**

Bharati Shetty
Company Secretary and Compliance Officer
(Membership No.: ACS 24199)

Encl.: As above

Bayer CropScience Ltd.
CIN: L24210MH1958PLC011173

Registered and Corporate Office:
Bayer House
Central Avenue
Hiranandani Estate
Thane (West) – 400 607
Maharashtra, India

Tel : +91 22 2531 1234
Fax : +91 22 2545 5063
www.bayer.in
www.cropscience.bayer.com

RESTRICTED

INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF BAYER CROPSCIENCE LIMITED

1. We have reviewed the Statement of Unaudited Financial Results of BAYER CROPSCIENCE LIMITED ("the Company"), for the quarter and nine months ended December 31, 2024 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations).
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)

MOHAMMED SAIFUDDIN BENGALI
Digitally signed by MOHAMMED SAIFUDDIN BENGALI
Date: 2025.02.11 18:15:33 +05'30'

Mohammed Bengali
(Partner)

Membership No. 105828
(UDIN: 25105828BMMLSA2484)

Place: Mumbai
Date: 11th February 2025



BAYER CROPSCIENCE LIMITED

(Registered Office: Bayer House, Central Avenue, Hiranandani Estate, Thane - 400 607, CIN L24210MH1958PLC011173)

₹ in Millions						
PART I						
STATEMENT OF FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2024						
PARTICULARS	Quarter Ended			Nine Months Ended		Year Ended
	31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	UNAUDITED	AUDITED
Revenue from Operations	10,569	17,376	9,549	44,257	43,117	51,032
Other Income	327	237	146	839	514	810
Total Income	10,896	17,613	9,695	45,096	43,631	51,842
Expenses						
Cost of Materials Consumed	6,913	10,703	3,639	26,074	21,948	27,184
Purchases of Stock-in-Trade	288	509	173	1,308	1,083	1,393
Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(618)	707	1,472	965	2,317	539
Employee Benefits Expense	1,231	1,159	1,139	3,386	3,080	4,354
Finance Costs	37	34	31	113	147	196
Depreciation and Amortisation Expense	151	140	152	506	581	740
Impairment of Non-current Assets (Note 2)	-	-	-	-	-	155
Other Expenses	2,558	2,460	1,847	7,349	6,115	7,867
Total Expenses	10,560	15,712	8,453	39,701	35,271	42,428
Profit Before Tax	336	1,901	1,242	5,395	8,360	9,414
Tax Expense						
- Current Tax	20	540	309	1,164	1,871	1,984
- Deferred Tax	(26)	(2)	2	(16)	44	25
Total Tax Expense	(6)	538	311	1,148	1,915	2,009
Profit for the period/ year	342	1,363	931	4,247	6,445	7,405
Other Comprehensive Income						
Items that will not be reclassified to profit or loss:						
- Remeasurement of Defined Benefit Obligation	(9)	(2)	(38)	(14)	(2)	47
- Tax on remeasurement of Defined Benefit Obligation	3	-	9	4	-	(12)
Total Other Comprehensive Income	(6)	(2)	(29)	(10)	(2)	35
Total Comprehensive Income for the period/ year	336	1,361	902	4,237	6,443	7,440
Paid up Equity Share Capital (Face Value ₹ 10/-)	449	449	449	449	449	449
Reserves (excluding Revaluation Reserve as per Balance Sheet)						28,045
Earnings per share (basic and diluted) (*not annualised) in ₹	7.61*	30.33*	20.72*	94.5*	143.41*	164.77

NOTES:

- The Company has only one reportable business segment, i.e. "Agri Care". The Company's business is seasonal in nature and hence quarterly figures are not necessarily representative of the full year's performance.
- It represents impairment of Glyphosate based products manufacturing plant (an item of Property, plant and equipment including Capital work-in-progress and Intangible Assets). The recoverable value of these assets was lower than its carrying value due to significant change in market dynamics impacting margins, which resulted in the impairment loss.
- The above results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on February 11, 2025. The above results have been subjected to limited review by the Statutory Auditors of the Company.

By Order of the Board

SIMON
JOHANNES
BRITSCH

Digitally signed by
SIMON JOHANNES
BRITSCH
Date: 2025.02.11
18:03:17 +05'30'

Simon Johannes Britsch
Executive Director & Chief Financial Officer
DIN: 09194547

Place: Mumbai
Date: February 11, 2025